MRNA · Moderna, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $103.2B |
| P/E | — |
| Float | 369.9M |
| Beta | 1.25 |
| Volatility 30D | 99.5% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 19.5 |
| Price | 239.14 |
| Change | −7.45% |
| Prev Close | 258.38 |
| Open | 235.00 |
| Day Low | 230.21 |
| Day High | 258.72 |
| Avg Vol | 17 |
| Avg $ Vol | $4.45B |
| 52W High | 258.38 |
| 52W Low | 22.28 |
| 52W Pos | 91.9% |
| From High | −7.45% |
| From Low | +973.34% |
| Max DD 1Y | −34.16% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +8.12% |
| SMA 50 | +27.35% |
| SMA 200 | +167.20% |
| RSI (14) | 68.1 |
| Vol 90D | — |
| Vol 1Y | — |
| 1Y Range | 22–258 |
| Daily bars | 549 |
| Perf Week | +20.65% |
| Perf Month | +37.83% |
| Perf Quarter | +379.73% |
| Perf Half Y | +429.58% |
| Perf Year | +937.25% |
| Perf YTD | +674.92% |
| Prev Day | −7.45% |
| Clavix | F |
| Debt / Eq | 0.07 |
| Curr Ratio | 3.29 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | −39.9% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 35 / 35 |
What MRNA does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Clavix risk grade
regraded every trading dayMRNA grades F, 19.5 of 100. Steadiest on News Sentiment (56), most exposed on Price Stability (3, weak). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 35 of 35 in Biotechnology by Clavix score.
How rough the ride is
| MRNA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.25 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 99.5% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −34.2% | — |
| Typical daily movemedian absolute daily change | 2.69% | — |
| Days beyond ±3%of the last 252 sessions | 116 (46%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MRNA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.25 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MRNA | |
|---|---|
| 1 week | +20.6% |
| 1 month | +37.8% |
| Year to date | +674.9% |
| 1 year | +937.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MRNA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 17 Oct |
| Average score0 most bearish, 100 most bullish | 61 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 4 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| MRNA | |
|---|---|
| Revenue growthyear over year | −39.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article highlights Intismeran, a cancer vaccine that has shown high effectiveness when used with Keytruda, and says Moderna and Merck are evaluating it for multiple cancers. It asks whether Moderna's stock could double but provides no financial data or analysis supporting that possibility.
In a recent clinical trial, Moderna's cancer vaccine intismeran combined with Merck's Keytruda reduced the risk of death or recurrence for melanoma patients by 42%.
Moderna and Merck are seeking FDA approval for a melanoma vaccine, and Moderna co-founder and board chairman Noubar Afeyan discussed the trial results and approval effort on Fox Business. The brief report provides no trial figures, filing details, FDA decision timeline, or other information from which to draw concrete implications.
Merck and Moderna reported Phase 3 results showing that personalized mRNA treatment intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death by 42% and the risk of cancer spreading to distant parts or death by 38% versus Keytruda alone in patients whose high-risk melanoma had been surgically removed. The article highlights the need to select cancer-specific targets and manufacture a separate dose for each patient but does not provide a quantified stock reaction.
Oppenheimer & Co. Inc., an investment manager, increased its holding of Moderna shares by 79.5% in the third quarter, according to its latest quarterly holdings filing with the SEC. The fund reported owning 15,824 Moderna shares after the increase; the supplied text ends before stating the stake's dollar value.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | B+ | $96.26B | 20.90 | 0.10 | Compare |
| VRTX | Vertex Pharmaceuticals Incorporated | B+ | $141.7B | 33.92 | 0.24 | Compare |
| NTRA | Natera, Inc. | B- | $56.36B | — | 1.57 | Compare |
| GILD | Gilead Sciences, Inc. | A- | $216.4B | 25.43 | 0.38 | Compare |
| RVMD | Revolution Medicines, Inc. | B- | $42.80B | — | 1.49 | Compare |
| AMGN | Amgen Inc | A- | $258.7B | 28.52 | 0.40 | Compare |
| BIIB | Biogen Inc. | B+ | $37.61B | 44.18 | 0.08 | Compare |
| UTHR | United Therapeutics Corporation | B+ | $25.68B | 19.44 | 0.45 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.